CLGN Overview

Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.

Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.

Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.

Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

Expansion of Operations: CollPlant is set to enhance its North American distribution of rhCollagen and BioInk products through a new partnership with a U.S.-based logistics center, which will improve operational efficiency and support its growing customer base.

Innovative Developments: The company has made significant strides in its dermal filler program and has reported successful preclinical results, including the creation of a fully humanized bioprinted skin model, showcasing the potential of its rhCollagen technology as a non-animal alternative for medical research.

Financial Performance: CollPlant reported a notable increase in revenues for the third quarter of 2025, driven by sales of rhCollagen-based products and a milestone payment from AbbVie, while also implementing cost reduction measures that include a workforce reduction of approximately 25%.

Future Plans: The company aims to prioritize its collaboration with AbbVie and continue advancing its dermal filler product candidate, while also seeking strategic partnerships for the development of its regenerative breast implant product.

Financial Results Announcement: CollPlant Biotechnologies will report its third-quarter financial results for 2025 on November 26, 2025, before U.S. market opening.

Company Overview: CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting and products based on non-animal-derived rhCollagen for tissue regeneration.

Partnership with Allergan: In 2021, CollPlant entered a global commercialization agreement with Allergan, a leader in the dermal filler market, for the development of dermal and soft tissue fillers.

Contact Information: For further inquiries, CollPlant's Deputy CEO & CFO, Eran Rotem, and investor relations contact, Daniel Ferry, are available for communication.